Seminal Trial Series: Crizotinib in PROFILE 1001

Podcast | English | 2024 | 56 Min

Create Account

Cost

$0.00

Credit

No Credit Offered

In this special episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu moderate a discussion on the seminal PROFILE-1001 trial that brought us the versatile tyrosine kinase inhibitor crizotinib. Crizotinib was the first approved ALK inhibitor and the first approved ROS1 inhibitor, and it played a huge role in the emergence of the targeted therapy paradigm.

Podcast Hosts:

Narjust Florez, MD, Associate Director of the Cancer Care Equity Program and Thoracic Medical Oncologist, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School, Boston, MA, USA
Stephen Liu, MD, Associate Professor of Medicine, Director of Thoracic Oncology and Director of Developmental Therapeutics, Georgetown Lombardi Comprehensive Cancer Center, Washington, D.C., USA

Podcast Guests:

Ignatius Ou, MD, Professor of Medicine and Hamoui Salous Edowed Chair in Thoracic Oncology Research, University of California, Irvine, CA, USA
Alice Shaw, MD, Chief of Strategic Partnerships, Dana Farber Cancer Institute, Board Member of the American Association of Cancer Research, Boston, MA, USA
Benjamin Solomon, PhD, MBBS, FRACP, Professor and Consultant Medical Oncologist, Peter MacCallum Cancer Centre, Melbourne, Australia